| Literature DB >> 26367137 |
Kim Aubin1, Meryem Safoine1, Maryse Proulx1, Marie-Alice Audet-Casgrain2, Jean-François Côté2, Félix-André Têtu3, Alphonse Roy4, Julie Fradette5.
Abstract
Representative modelling of human adipose tissue functions is central to metabolic research. Tridimensional models able to recreate human adipogenesis in a physiological tissue-like context in vitro are still scarce. We describe the engineering of white adipose tissues reconstructed from their cultured adipose-derived stromal precursor cells. We hypothesize that these reconstructed tissues can recapitulate key functions of AT under basal and pro-inflammatory conditions. These tissues, featuring human adipocytes surrounded by stroma, were stable and metabolically active in long-term cultures (at least 11 weeks). Secretion of major adipokines and growth factors by the reconstructed tissues was determined and compared to media conditioned by human native fat explants. Interestingly, the secretory profiles of the reconstructed adipose tissues indicated an abundant production of leptin, PAI-1 and angiopoietin-1 proteins, while higher HGF levels were detected for the human fat explants. We next demonstrated the responsiveness of the tissues to the pro-inflammatory stimulus TNF-α, as reflected by modulation of MCP-1, NGF and HGF secretion, while VEGF and leptin protein expression did not vary. TNF-α exposure induced changes in gene expression for adipocyte metabolism-associated mRNAs such as SLC2A4, FASN and LIPE, as well as for genes implicated in NF-κB activation. Finally, this model was customized to feature adipocytes representative of progressive stages of differentiation, thereby allowing investigations using newly differentiated or more mature adipocytes. In conclusion, we produced tridimensional tissues engineered in vitro that are able to recapitulate key characteristics of subcutaneous white adipose tissue. These tissues are produced from human cells and their neo-synthesized matrix elements without exogenous or synthetic biomaterials. Therefore, they represent unique tools to investigate the effects of pharmacologically active products on human stromal cells, extracellular matrix and differentiated adipocytes, in addition to compounds modulating adipogenesis from precursor cells.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26367137 PMCID: PMC4569087 DOI: 10.1371/journal.pone.0137612
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Description of AT used for organotypic cultures and/or tissue reconstruction.
|
|
|
|
|
|
|
|
| |||||
| 1 | 32 | 23.3 | 610.0 (76.7) | 6 | Basal secretion |
| 2 | 35 | 21.0 | 1807.7 (380.5) | 3 | Basal secretion |
| 3 | 36 | 25.0 | 870.2 (136.2) | 3 | Basal secretion |
| 4 | 38 | 20.1 | 467.4 (120.8) | 6 | Basal secretion |
| 5 | 41 | 28.8 | 867.2 (70.1) | 4 | Basal secretion |
| 6 | 55 | 25.3 | 486.9 (100.3) | 6 | Basal secretion |
|
|
|
|
|
|
|
| 51 | 22.0 | 806.2 (123.8) | 3 | 10 ng/ml TNF-α 24 h- treatment | |
| 7 | 51 | 22.0 | 791.7 (52.0) | 3 | Control, non-treated samples |
| 58 | 24.6 | 233.6 (35.0) | 3 | 10 ng/ml TNF-α 24 h- treatment | |
| 8 | 58 | 24.6 | 232.1 (11.1) | 3 | Control, non-treated samples |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||
| 3 | 36 | 25.0 | 30.1 (1.8) / 31.8 (1.3) | 2 / 3 | Basal secretion |
| 6 | 55 | 25.3 | 29.6 (2.2) / 26.1 (0.5) | 3 / 3 | Basal secretion |
| 9 | 38 | 29.5 | 28.1 (0.7) / 39.1 (0.9) | 2 / 3 | Basal secretion |
| 10 | 54 | 24.9 | 26.3 (1.9) / 18.5 (1.7) | 3 / 3 | Basal secretion |
|
|
|
|
|
|
|
*: Values are indicated as mean (SD) when applicable.
&: indicates tissues from male donors.
#: indicates data available for both AT explants and tissues reconstructed using the cells extracted from adipose tissue from the same donor.
Primer sequences and gene description.
| Gene Symbol | Description | GenBank | size (pb) | Primer sequence 5'→3' S/AS |
|---|---|---|---|---|
|
| Homo sapiens chemokine (C-C motif) ligand 2 (CCL2) | NM_002982 | 188 | GCAGCCACCTTCATTCCCCAA/GCACAGATCTCCTTGGCCACA |
|
| Homo sapiens solute carrier family 2 (facilitated glucose transporter), member 4 (SLC2A4) | NM_001042 | 212 | CCAGTATGTTGCGGAGGCTAT/CGTTCTCATCTGGCCCTAAATACT |
|
| Homo sapiens lipase, hormone-sensitive (LIPE) | NM_005357 | 191 | GAAGACTCTGCAGGGATCCAATA/TTTGGATGTAAGGTGATTGCTGTGG |
|
| Homo sapiens fatty acid synthase (FASN) | NM_004104 | 257 | TGCGTGGCCTTTGAAATGTGCT/ACACGCTCCTCTAGGCCCTTCA |
|
| Homo sapiens nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (NFKB1), 2 transcripts | NM_003998 | 180 | AGCCTCTCTATGACCTGGATGACT/GCTGTTTCATGTCTCCTTGTGCTAGT |
|
| Homo sapiens nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100) (NFKB2), 4 transcripts | NM_001077494 | 256 | ACGAACAGCCTTGCATCTAGCC/CCCTTCAGAGTCCGAGTCGCT |
|
| Homo sapiens nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (NFKBIA) | NM_020529 | 143 | TACCTGGGCATCGTGGAGCTT/TCAGCCCCACACTTCAACAGGA |
|
| Homo sapiens inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta (IKBKB), 8 transcripts | NM_001556 | 215 | GCCGTGAGAAAAGTGCTTGGAG/GGCCGCAACTATAATTAAACTGTCTG |
|
| Homo sapiens TNF receptor-associated factor 1 (TRAF1), 3 transcripts | NM_005658 | 244 | AACCCATCTGTCGCTCTTCATC/GTAGGCGTGCTTGGGTGACTG |
|
| Homo sapiens tumor necrosis factor, alpha-induced protein 3 (TNFAIP3), 3 transcripts | NM_001270508 | 241 | GGCCTCTTTGATACACTTTTGCT/ACCATCACAAAAGGCCACATCT |
|
| Homo sapiens baculoviral IAP repeat containing 3 (BIRC3), 2 transcripts | NM_001165 | 171 | TTCATCCGTCAAGTTCAAGCCAGT/CACGGCAGCATTAATCACAGGA |
|
| Homo sapiens B-cell CLL/lymphoma 2 (BCL2), 2 transcripts | NM_000633 | 98 | GGTGGGGTCATGTGTGTGGAGAG/TGCAGGTGCCGGTTCAGGTACT |
|
| Homo sapiens jun proto-oncogene (JUN) | NM_002228 | 229 | CGGCCAACATGCTCAGGGAAC/ACCCTTGGCTTTAGTTCTCGGACAC |
|
| Homo sapiens ubiquitin C (UBC) | NM_021009 | 127 | CTCGGCCTTAGAACCCCAGTA/AGAATCGCCGAGAAGGGACTAC |
|
| Homo sapiens glucuronidase, beta (GUSB) | NM_000181 | 130 | CGACGAGAGTGCTGGGGAATA/TTGGCTACTGAGTGGGGATACCT |
|
| Homo sapiens TATA box binding protein (TBP), 2 transcripts | NM_003194 | 189 | CGGGCACCACTCCACTGTATC/GCTTGGGATTATATTCGGCGTTTC |
|
| Homo sapiens 3-beta-hydroxysteroid dehydrogenase/delta-5-delta-4-isomerase (3-beta-HSD) gene (intron) | M38180 | 260 | GAAGGGCAGAGGTGGAACTAGAA/AACAAAGACCAAAGACCAGTGAGA |
Fig 1Morphological features of hrAT.
The structural appearance of the hrAT engineered in vitro is revealed on tissue cross-sections after Masson’s trichrome staining. (A-C) Numerous adipocytes embedded in ECM can be distinguished within tissues submitted to adipogenic induction after 7 days of culture and differentiated for (A) 28, (B) 49 and (C) 81 days. (D) Histology of human native subcutaneous AT from a 54 year-old donor. (E) Scanning electron microscopy exposes rounded adipocytes (25 days of differentiation) in the matrix-rich hrAT. The arrow points to a region of the hrAT revealing the sheet-like structure. (F) Appearance by SEM of adipocytes from a 58 year-old donor. Lipids within adipocytes from (G) hrAT and (H) AT samples can be observed after Nile Red staining. Staining for collagen type IV on (I) hrAT and (J) native AT reveals its localization in basement membranes. (K) and (L) represent isotype antibody controls for labeling of hrAT and native AT, respectively. Asterisk (*): blood capillary.
Fig 2Long-term stability of the hrAT in vitro.
(A) Mean surface area of the adipocytes over the culture period as measured from histological sections of hrAT harvested after 28, 49 or 81 days of in vitro differentiation. (B) Frequency distribution of adipocyte cell surface area according to the number of days the tissues were maintained in culture after adipogenic induction. Mean ± SEM. One-way ANOVA followed by Tukey’s post-hoc tests were performed and the significance is indicated in reference to day 28 (*) or day 49 (#). ***P≤0.001, **P≤0.01, * and # P≤0.05. (C) Kinetics of Ang-1 secretion in media conditioned by reconstructed cell sheets maintained in culture up to 49 days. Connective sheets were produced using the same cells as adipose sheets but without the adipogenic induction step. Results are expressed as ng/ml/48 h per sheet of 3.5 cm2. Data from cell sheets engineered from three distinct cell populations is represented (N = 3, n = 2–3 for each time-point). Mean ± SD, # indicates statistical difference between connective and adipose sheets at each time-point (P≤0.05, unpaired t-tests) while asterisks (*) indicate the comparison between consecutive weeks within the same cell population. & indicates that all three populations are significantly different between consecutive weeks. One-way ANOVA followed by Tukey’s post-hoc test. **** P≤0.0001, *** P≤0.001, **P≤0.01, * and & P≤0.05.
Fig 3Secretion of key adipokines by AT explants and reconstructed tissues.
Culture media conditioned for 48 h by AT explants (N = 6 donors, n = 3–6 per donor) as well as hrAT (28 days of differentiation) and their hrCT undifferentiated counterparts (N = 4, n = 2–3) were analyzed by ELISA assays. Secreted levels of (A) leptin, (B) PAI-1, (C) Ang-1, (D) VEGF and (E) HGF were determined. Data are expressed as pg/ml of molecule secreted in 48 h normalized by total DNA content (means ± SEM). Each datapoint represents the mean value obtained for many samples derived from a distinct donor/population (Table 1). (F) Total DNA content determination. One-way ANOVA followed by Tukey’s post-hoc test. ***P≤0.001, **P≤0.01, *P≤0.05. ND = not detected.
Gene expression in adipose sheets is modulated by TNF-α exposure.
| Gene symbol | Fold variation over control | |||||
|---|---|---|---|---|---|---|
| Treatment duration | 6 h | 24 h | 72 h | |||
| [TNF] (ng/ml) | 10 | 100 | 10 | 100 | 10 | 100 |
|
| -1.1 | -1.1 | -1.2 | -1.2 | -1.0 | -1.2 |
|
|
|
|
|
| ||
|
| 2.3 | 2.6 | 1.7 | 2.0 | 1.8 | 3.8 |
|
|
|
|
|
|
| |
|
| 9.8 | 8.7 | 4.4 | 9.6 | 2.3 | 4.4 |
|
|
|
|
|
| ||
|
| -1.3 | -1.3 | -2.2 | -2.5 | 1.0 | -1.4 |
|
|
|
|
|
| ||
|
| -1.6 | -1.5 | -1.7 | -2.1 | 1.0 | -2.8 |
|
|
|
|
|
| ||
|
| -2.2 | -3.2 | -1.8 | -2.8 | -1.5 | -3.2 |
|
|
|
|
|
| ||
|
| 3.5 | 3.9 | 4.1 | 5.4 | 1.1 | 3.3 |
|
|
|
|
|
| ||
|
| -1.0 | 1.2 | 1.0 | 1.1 | -1.1 | 1.1 |
|
| ||||||
|
| 1.1 | 1.1 | 1.1 | 1.2 | 1.2 | 1.3 |
|
|
|
| ||||
|
| 7.3 | 7.8 | 2.3 | 3.3 | 1.5 | 3.4 |
|
|
|
|
|
|
| |
|
| 7.3 | 9.3 | 3.6 | 5.8 | 1.5 | 4.8 |
|
|
|
|
|
|
| |
|
| 1.7 | 1.7 | 1.2 | 1.3 | 1.0 | 1.2 |
|
|
|
|
|
| ||
|
| 9.5 | 12.7 | 4.9 | 9.7 | 1.8 | 8.6 |
|
|
|
|
|
|
| |
|
| 37.1 | 38.7 | 15.8 | 34.6 | 3.0 | 28.6 |
|
|
|
|
|
|
| |
|
| 25.3 | 35.3 | 13.4 | 29.7 | 2.4 | 25.6 |
|
|
|
|
|
|
| |
|
| 12.2 | 21.7 | -1.1 | 3.4 | -1.3 | 1.4 |
|
|
|
|
| |||
|
| 10.0 | 15.0 | 2.9 | 5.6 | 1.3 | 10.5 |
|
|
|
|
|
|
| |
|
| 3.0 | 3.3 | 1.2 | 2.1 | 1.3 | 2.3 |
|
|
|
|
| |||
(-) indicates a decrease in expression.
# Statistical analyses were performed for each time-point using one-sample t-tests comparing fold variation ratio of each TNF-α condition to the untreated controls (value of 1).
(****P≤0.0001
***P≤0.001
**P≤0.01
*P≤0.05).
Fig 4Effects of TNF-α on adipokine secretion by reconstructed tissues and AT explants.
(A) Dose-dependent release of MCP-1 after exposure to TNF-α. Adipose cell sheets were incubated for 24 h in presence of 10 or 100 ng/ml of TNF-α and the conditioned media were analyzed by ELISA assays. One-way ANOVA followed by Tukey’s post-hoc test. ***P≤0.001 compared to control, ## P≤0.01 compared to 10 ng/ml TNF-α. (B) Fold increase protein expression over control for MCP-1, free NGF, HGF, VEGF and leptin following a 24 h exposition of adipose sheets to 10 or 100 ng/ml TNF-α. (C) Fold increase protein expression over control for MCP-1, HGF and VEGF following a 24 h exposition of connective sheets to 10 or 100 ng/ml TNF-α. For each molecule, one-sample t-tests were performed in reference to untreated sheets (ratio of 1). For B and C, One-way ANOVA followed by Dunnett’s post-hoc test ****P≤0.0001, ***P≤0.001, **P≤0.01. (D) Comparative amounts (ng/ml) of MCP-1, HGF and VEGF secreted by the connective and adipose cell sheets following a 24 h exposure to 10 ng/ml TNF-α. Dashed lines within each column indicate the basal level of mock-treated connective and adipose sheets for the corresponding secreted protein. # indicates statistical significance for these basal levels between connective and adipose sheets while asterisks (*) indicate significance between tissue types. ****P≤0.0001, **P≤0.01, *P≤0.05. Note that leptin is not produced by connective sheets or hrCT. (E) Fold increase protein expression over control for MCP-1, HGF, VEGF and leptin following a 24 h exposition of human AT explants to 10 ng/ml TNF-α. Data normalization was performed according to the weight of the explants.
Gene expression in connective sheets is modulated by TNF-α exposure.
| Gene symbol | Fold variation over control | |||||
|---|---|---|---|---|---|---|
| Treatment duration | 6 h | 24 h | 72 h | |||
| [TNF] (ng/ml) | 10 | 100 | 10 | 100 | 10 | 100 |
|
| -1.1 | -1.1 | -1.3 | -1.4 | -1.1 | -1.6 |
|
|
|
|
| |||
|
| 1.8 | 1.7 | 1.8 | 2.1 | 1.6 | 4.5 |
|
|
|
|
|
|
| |
|
| 4.9 | 4.8 | 5.1 | 8.6 | 2.3 | 9.9 |
|
|
|
|
|
|
| |
|
| 3.2 | 3.3 | 4.4 | 6.9 | 1.3 | 10.4 |
|
|
|
|
|
| ||
|
| 1.0 | 1.2 | -1.1 | -1.1 | -1.2 | -1.2 |
|
|
|
| ||||
|
| 1.1 | 1.0 | -1.2 | -1.1 | 1.0 | -1.0 |
|
| ||||||
|
| 4.4 | 4.5 | 2.1 | 3.5 | 1.4 | 3.1 |
|
|
|
|
|
|
| |
|
| 4.0 | 5.2 | 2.8 | 4.5 | 1.7 | 4.9 |
|
|
|
|
|
|
| |
|
| 1.5 | 1.5 | 1.1 | 1.1 | -1.0 | 1.2 |
|
|
|
|
| |||
|
| 5.3 | 6.7 | 4.4 | 8.4 | 1.8 | 7.6 |
|
|
|
|
|
|
| |
|
| 9.8 | 11.2 | 13.3 | 26.7 | 4.0 | 30.3 |
|
|
|
|
|
|
| |
|
| 12.1 | 15.5 | 5.0 | 12.8 | 2.2 | 19.9 |
|
|
|
|
|
|
| |
|
| 7.7 | 13.4 | 5.9 | 12.0 | 1.1 | 12.9 |
|
|
|
|
|
| ||
|
| 8.1 | 9.5 | 2.9 | 4.8 | 1.2 | 3.3 |
|
|
|
|
|
| ||
|
| 1.4 | 1.5 | -1.3 | -1.2 | -1.1 | -1.1 |
|
|
|
|
| |||
(-) indicates a decrease in expression.
# Statistical analyses were performed for each time-point using one-sample t-tests comparing fold variation ratio of each TNF-α condition to the untreated controls (value of 1).
(****P≤0.0001
***P≤0.001
**P≤0.01
*P≤0.05).
Fig 5Engineering of hrAT featuring adipocytes representative of various stages of differentiation.
(A) Schematic representation of the induction schemes leading to the production of the hrAT shown in (C). (B) Intracellular lipid quantification following Oil Red O staining of adipose sheets reconstructed according to static or dynamic culture conditions. While the induction of adipogenesis was performed at different times (day 7, 14 or 21) of culture in presence of AsA, Oil Red O staining was carried out after a fixed period of 14 days during which lipid accumulation proceeded. *P≤0.05, One-way ANOVA followed by Tukey’s post-hoc test; ### P = 0.0003, && P = 0.0013, paired t-tests between dynamic and static conditions at a given day of induction. (C) Histological cross-sections of hrCT (no adipocytes) and hrAT featuring smaller or more developed adipocytes according to the day at which induction of adipogenesis was performed under dynamic culture conditions. Masson’s trichrome staining on paraffin-embedded hrAT samples (left) show the presence of numerous adipocytes (void spaces) and important ECM content (blue), while Oil Red O staining (right) on formol-fixed cryosections reveals the accumulation of intracellular lipids by the developing adipocytes. Bars = 100 μm.